Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

tirzepatide (Zepbound)

Adjunctive therapy

Brand: ZEPBOUND

Published 2026-02-05 · Last reviewed 2026-02-12 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Typical: titrate to a maintenance dose of 5 mg, 10 mg, or 15 mg subcutaneously once weekly (start 2.5 mg once weekly for 4 weeks; increase in 2.5 mg steps after at least 4 weeks at each dose) (label).·Half-life: Single-dose mean 120 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Typical: titrate to a maintenance dose of 5 mg, 10 mg, or 15 mg subcutaneously once weekly (start 2.5 mg once weekly for 4 weeks; increase in 2.5 mg steps after at least 4 weeks at each dose) (label).
Half-life: Single-dose mean 120 h
LAI available: No

Quick answers

What is tirzepatide (Zepbound)?: Zepbound is a once-weekly injectable form of tirzepatide, a dual GIP/GLP-1 receptor agonist indicated for chronic weight management with diet and exercise (label).
What is ZEPBOUND?: ZEPBOUND is a brand name for tirzepatide (Zepbound).
What is ZEPBOUND (tirzepatide (Zepbound)) used for?: Label indications include: Chronic weight management (with diet and exercise) in adults with obesity or overweight with weight-related comorbidities (label). No FDA-approved psychiatric indications.
What drug class is ZEPBOUND (tirzepatide (Zepbound))?: GIP/GLP-1 Agonist.
What is the mechanism of action of ZEPBOUND (tirzepatide (Zepbound))?: Weekly injectable dual GIP/GLP-1 receptor agonist (tirzepatide) indicated for chronic weight management (with diet and exercise). It has no FDA-approved psychiatric indications but may be considered in psychiatric populations for cardiometabolic risk reduction with careful monitoring for mood changes (label/clinical).
What strengths does ZEPBOUND (tirzepatide (Zepbound)) come in?: Single-dose pens for subcutaneous injection once weekly (label).

General information

Zepbound is a once-weekly injectable form of tirzepatide, a dual GIP/GLP-1 receptor agonist indicated for chronic weight management with diet and exercise (label).

It is not a psychiatric medication. In psychiatric populations it may be discussed as a metabolic risk-reduction tool (obesity and cardiometabolic risk), including in people taking weight-gain–promoting psychotropics (clinical).

Zepbound includes warnings with particular relevance to psychiatric populations: boxed warning for thyroid C-cell tumors and a warning to monitor for suicidal behavior and ideation (label).

A high-impact practical warning is reduced efficacy of oral hormonal contraceptives during initiation and dose escalation due to delayed gastric emptying; contraception counseling should be explicit and proactive (label).

The compare view, evidence feed, and print page help compare titration schedules and monitoring themes.

U.S. approvals

Chronic weight management in adults with obesity or overweight with weight-related comorbidities (2023)

Formulations & strengths

Single-dose pens for subcutaneous injection once weekly (label).
Dose strengths include 2.5 mg through 15 mg pens (label).

Generic availability

Not available generically (brand-only).

For psychiatric populations, feasibility often depends on coverage, follow-up capacity during titration, and coordination across prescribers. Because a warning exists for suicidal behavior/ideation, plans should include a clear monitoring and escalation pathway for new or worsening mood symptoms (label/clinical).

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Clinically it supports weight reduction through incretin-based metabolic signaling, appetite effects, and delayed gastric emptying (label/clinical).

In mental health care, the practical aim is lowering metabolic risk without destabilizing psychiatric symptoms or adherence (clinical).

Dual GIP/GLP-1 receptor agonism (incretin-based metabolic signaling).
Appetite and satiety effects (clinical framing).

Metabolism & pharmacokinetics

Long half-life supports once-weekly dosing (approximately 5 days per labeling conventions).
Major CYP-mediated interactions are not expected (peptide metabolism), but delayed gastric emptying can affect absorption of some oral drugs during initiation and dose escalation (label/clinical).

Dosing & administration

Typical: titrate to a maintenance dose of 5 mg, 10 mg, or 15 mg subcutaneously once weekly (start 2.5 mg once weekly for 4 weeks; increase in 2.5 mg steps after at least 4 weeks at each dose) (label).
If a dose is missed, administer as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip the missed dose and resume the regular schedule. Do not take two doses within 3 days of each other (label).
Injection sites include abdomen, thigh, or upper arm; rotate sites (label).
GI tolerability often improves with slower escalation, smaller meals, and attention to hydration; severe vomiting warrants evaluation for dehydration and rare complications (clinical).

Monitoring & labs

Weight/BMI and waist circumference trend; document baseline and track response over time (clinical).
Monitor for new or worsening depression, suicidal thoughts/behaviors, and unusual mood changes; discontinue if symptoms develop (label).
Monitor for symptoms of pancreatitis and gallbladder disease (persistent severe abdominal pain, vomiting) (label).
Monitor for dehydration and renal function concerns when significant GI losses occur (label/clinical).
Contraception counseling for patients using oral hormonal contraceptives during initiation and dose escalation (label).

Consider coordination with primary care/endocrinology for cardiometabolic monitoring and for diabetes regimen changes when applicable (clinical).

Adverse effects

FDA boxed warnings

Risk of thyroid C-cell tumors; contraindicated with personal or family history of MTC or MEN2 (label).

Common side effects (≥10%)

Nausea / vomiting: Common during initiation and dose escalation; slower titration and meal-size adjustments often help (label/clinical).
Diarrhea / constipation: GI motility symptoms are common; hydration and dose pacing are common mitigations (label/clinical).
Decreased appetite: Appetite suppression is expected; monitor for dehydration and inadequate intake when symptoms are severe (clinical).
Injection-site reactions: Usually mild; rotate sites and monitor for persistent inflammation (label).

Other notable effects

Suicidal behavior and ideation warning: monitor for new or worsening depression, suicidal thoughts/behaviors, and unusual mood changes; discontinue if symptoms develop and avoid use in patients with active suicidal ideation (label).
Pancreatitis and gallbladder disease have been reported; evaluate severe or persistent abdominal pain and discontinue if pancreatitis is suspected (label).
Dehydration from vomiting/diarrhea can precipitate acute kidney injury; monitor volume status and renal function when clinically indicated (label/clinical).
Oral hormonal contraceptive efficacy can be reduced during initiation and dose escalation due to delayed gastric emptying (label).

Interactions

Oral hormonal contraceptives: advise patients to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation (label).
Delayed gastric emptying can affect absorption of some oral medications during titration; review narrow-therapeutic-index agents and time-sensitive regimens (clinical).

Other useful information

In serious mental illness care, ensure the monitoring plan covers both metabolic response and mental health safety (especially mood changes), and that follow-up is feasible during titration (label/clinical).

References

Related hubs:SMI toolkit·Support resources